Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Only 1 death in 94 pts with the last pt being enrolled nearly 2 and a half years ago with many enrolled before that. I wish they would have provided a historical control matching history to put it in context. But from post 1715

SOC OS for HER2 mBC at 1, 2, and 5 years is 86.6, 63.2, and 23.4% respectively. See Table 2 of Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review. The review is from 2010 but Standard of Care is Standard of Care

ascopubs.org/doi/full/10.1200/jco.2008.19.9844

So in the Korean study on 1 death in 94 pts with the last pt being enrolled nearly 2 and a half years ago with many enrolled before that, that's almost 99% as opposed to 63.2% at 2 yrs quoted above. Am I reading this wrong? Shouldn't they be shouting this from the rooftop? If they are seeing this trend, or better since they increased dosage/continuous dosing, in the US study, we will see them starting a P3 in 2018-2019.

Thanks for providing the pics. Are they available online? (can't really search where I'm at right now w weak internet connections).